GeneDx reported strong growth in its exome and genome testing business on Nov. 9, offsetting continued declines in other panels.
For the third quarter, the genetic testing company reported revenue of $123.1 million, up 5 percent year over year from $116.7 million, beating the consensus Wall Street estimate of $122.9.
Exome and genome revenue rose 12 percent year over year to $110.4 million from $98.9 million, with test volume up 25 percent to 32,134. Other panels revenue fell 34 percent to $9.7 million from $14.6 million. Total test volume fell slightly to 58,658 from 60,216 in the third quarter of 2025.
Net loss for the quarter was $12.3 million, or $0.41 per share, compared with a net loss of $7.6 million, or $0.27 per share, in Q3 2025. Adjusted EPS was $0.28, beating the consensus Wall Street estimate of $0.07 per share.
R&D expenses were $17.4 million, down from $19.8 million a year earlier. SG&A expenses rose 16 percent to $79.1 million from $67.9 million.
GeneDx ended the quarter with $171.1 million in cash, equivalents, marketable securities, and restricted cash.
The company reiterated its full-year 2026 revenue guidance of $475.0 million to $490.0 million but trimmed its outlook for exome and genome volume growth to at least 28 percent from at least 30 percent and for exome and genome revenue growth to at least 17 percent from at least 20 percent.
For the fourth quarter, GeneDx guided to revenue of $135.0 million.
